CGT Collaboration Moves from Aspirations to Infrastructure
Act for Hope founder Alexander Seyf says cell and gene therapy’s next challenge is not proving the science, but building a connected ecosystem that can turn breakthrough treatments into reliable, scalable, and equitable patient access. The post CGT Collaboration Moves from Aspirations to Infrastructure appeared first on GEN - Genetic Engineering and Biotechnology News .
Cell and gene therapy (CGT) has shown promise in tackling previously untreatable diseases, but delivering these advanced therapies at scale now depends on collaboration across stakeholders. Alexander Seyf, CEO of Act for Hope, argues that CGT requires a different model due to its complex lifecycle involving numerous parties. While the industry focuses on expanding manufacturing, Seyf emphasizes the need to scale collaboration.
By establishing shared standards, interoperable systems, and responsible data exchange, the ecosystem can bridge the gap between development and patient access. Fragmentation, caused by various processes, terminology, and technology platforms, creates inefficiencies that could hinder access. Act for Hope aims to provide a neutral platform for harmonizing these aspects without compromising intellectual property.
Two projects under development include a clinical-trial portal and a patient-access portal to improve patient access and coordination. Seyf believes that collaboration, alongside technology, will be crucial in translating CGT's scientific achievements into widespread patient treatments.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
